Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.

Autor: Feist E; Department of Rheumatology, Helios Fachklinik, Sophie-von-Boetticher-Straße 1, 39245, Vogelsang-Gommern, Germany. eugen.feist@helios-gesundheit.de.; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany. eugen.feist@helios-gesundheit.de.; Otto-von-Guericke University, Magdeburg, Germany. eugen.feist@helios-gesundheit.de., Baraliakos X; Rheumatology Center Ruhrgebiet Herne, Ruhr-University, Bochum, Germany., Behrens F; CIRI/Rheumatology and Fraunhofer IME, Institute for Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt/Main, Germany., Thaçi D; Institute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany., Klopsch T; Rheumatology Practice, Neubrandenburg, Germany., Plenske A; Pfizer Pharma GmbH, Berlin, Germany., Blindzellner LK; Pfizer Pharma GmbH, Berlin, Germany., Klaus P; Pfizer Pharma GmbH, Berlin, Germany., Meng T; Pfizer Pharma GmbH, Berlin, Germany., Löschmann PA; Pfizer Pharma GmbH, Berlin, Germany.
Jazyk: angličtina
Zdroj: Rheumatology and therapy [Rheumatol Ther] 2022 Apr; Vol. 9 (2), pp. 621-635. Date of Electronic Publication: 2022 Feb 03.
DOI: 10.1007/s40744-021-00418-5
Abstrakt: Background: For rheumatoid arthritis (RA), the treat-to-target concept suggests attaining remission or at least low disease activity (LDA) after 12 weeks.
Objectives: This German, prospective, multicenter, non-interventional study aimed to determine the proportion of patients with RA who achieved their treat-to-target aim after 12 and 24 weeks of etanercept (ETN) treatment in a real-life setting, as opposed to patients achieving their therapeutic target at a later timepoint (week 36 or 52).
Methods: A total of 824 adults with a confirmed diagnosis of RA without prior ETN treatment were included. Remission and LDA were defined as DAS28 < 2.6 and DAS28 ≤ 3.2, respectively.
Results: The proportion of patients achieving remission was 24% at week 12 and 31% at week 24. The proportion of patients achieving LDA was 39% at week 12 and 45% at week 24. The proportion of patients achieving remission or LDA further increased beyond week 24 up to week 52. Improvement in pain and reduction in concomitant glucocorticoid treatment were observed. Improvements in patient-reported outcomes were also seen in patients who did not reach remission or LDA. No new safety signals were detected.
Conclusions: A considerable proportion of patients with RA attained the target of remission or LDA after 12 weeks of ETN treatment. Even beyond that timepoint, the proportion of patients achieving treatment targets continued to increase up to week 52.
Trial Registration: ClinicalTrials.gov Identifier: NCT02486302.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje